Initiates Phase

Related by string. initiate Phase * initiates . initiate : initiate impeachment proceedings . initiates coverage / phase : Phase III clinical trials * Initiates Phase II . initiate Phase IIb . initiate Phase IIa . initiate Phase 2b . initiate Phase Ib . initiate Phase 2a . Initiate Phase II . Initiates Phase 2b . initiate Phase 1b . Initiates Phase III . Initiate Phase III *

Related by context. All words. (Click for frequent words.) 87 Commences Phase 86 Initiates Phase II 86 Initiate Phase 85 Completes Patient Enrollment 85 Completes Enrollment 84 Successfully Completes Phase 82 Meets Primary Endpoint 82 Initiates Phase III 82 Pivotal Phase 82 Presents Positive 81 Receives Orphan Drug Designation 81 Phase 2b Clinical Trial 81 Presents Preclinical Data 81 Initiates Clinical 80 Randomized Phase 80 Commence Phase 80 Announces Initiation 79 Initiates Clinical Trial 79 Initiates Enrollment 79 Initiates Phase 2b 79 Drug Candidate 79 Files IND 78 Begins Dosing 78 Trial Evaluating 78 Pivotal Phase III 78 Present Preclinical Data 77 Phase IIb Trial 77 Presents Preclinical 77 Phase IIb Clinical Trial 77 Novel Oral 77 Initiates Dosing 77 Phase 2b Trial 77 Preclinical Data 76 Submits IND 76 Enrolls First 76 Study Evaluating 76 Clinical Trial Results 76 Receives Milestone Payment 76 Submits NDA 76 Initiate Phase III 75 Granted Orphan Drug 75 Announces Positive 75 dependent kinase inhibitor 75 PRN FDA Approves 75 FDA Accepts 75 Announces Publication 75 Phase III Clinical Trial 75 Demonstrates Significant 75 Initiates Clinical Trials 74 pralatrexate injection folate analogue 74 Completes Dosing 74 Collaborators Present 74 R roscovitine CDK cyclin 74 Presents Positive Preclinical 74 Phase III Pivotal 74 Patient Enrollment 74 Hsp# Inhibitor 74 Reports Preclinical Data 74 Demonstrates Positive 74 Receives Orphan Drug 74 Phase 2a Trial 74 Phase IIa Clinical Trial 74 TKB# 74 Initiated Phase 74 Previously Treated 74 Receives Fast Track 74 Protease Inhibitor 74 JAK2 Inhibitor 74 Therapeutic Competitors Companies 74 Submits Biologics License Application 73 Multiple Ascending Dose 73 Announce Initiation 73 Metastatic Melanoma 73 Spectrum Pharmaceuticals Announces 73 Earns Milestone Payment 73 Achieves Primary Endpoint 73 Announces Presentation 73 Files Investigational 73 Receives Approvable Letter 73 Chronic Hepatitis C 73 Investigational Oral 73 Confirmatory Phase 73 Kinase Inhibitor 73 Single Dose 73 Clinical Trial Evaluating 73 Prolongs Survival 73 Agonist MABA program 73 Initiate Clinical Trial 73 Phase III Trial 73 Phase 2a Clinical Trial 72 Adjunctive Therapy 72 Combination REOLYSIN R 72 FDA Approves 72 First Patient Dosed 72 Phase 1b Clinical Trial 72 Second Pivotal Phase 72 Announces Successful Completion 72 Announces Poster Presentations 72 Licenses Novel 72 Receives FDA Clearance 72 Pooled Analysis 72 Completes Patient Enrolment 72 Reports Positive 72 drug pipeline TAFA# 72 Dose Ranging Study 72 Investigational Compound 72 Submits Response 72 Receptor Antagonist 72 Adjuvant Treatment 72 Randomized Phase II 72 II Clinical Trial 72 FDA Clears 72 Vaccine Adjuvant 72 Antitumor Activity 72 AAG geldanamycin analog 72 Oral Fingolimod 72 Nasdaq XTLB 72 Reveals Positive 72 oral nucleoside analogue 72 Complicated Skin 72 Mylan Receives Approval 72 Drug Fails 71 Improves Survival 71 developing Bicifadine serotonin 71 Taro Receives 71 oral prodrug 71 Announce License Agreement 71 initiated Phase Ib 71 Well Tolerated 71 Telaprevir VX 71 MKC# MT 71 Pivotal Study 71 Oral Calcitonin 71 Humanized Anti 71 Patients Treated With 71 Orally Active 71 Randomized Double Blind 71 Announces Tentative Approval 71 Demonstrates Potential 71 Receives NASDAQ 71 non nucleoside inhibitor 71 Sapacitabine 71 Commences Phase III 71 FOLOTYN ® 71 Hormone Refractory Prostate Cancer 71 Receptor Agonist 71 Treatment Naïve 71 IND Application 71 Recombinant Human 70 TO AVOID PREGNANCY WHILE 70 Reacquires 70 Refractory Hodgkin Lymphoma 70 Monoclonal Antibody 70 Sign Licensing Agreement 70 Shows Promise 70 Fast Track Status 70 Anti Tumor 70 PEGylated Fab fragment 70 Demonstrated Significant 70 Tezampanel 70 Pharmacokinetic Study 70 Testosterone MDTS ® 70 Receives Positive Opinion 70 immunosuppressive compound 70 First Patient Enrolled 70 Announces Dosing 70 Demonstrates Potent 70 Severe Sepsis 70 Xcytrin R 70 VEGFR2 inhibitor 70 pan histone deacetylase 70 Advanced Melanoma 70 Phase 2b Study 70 markets Testim ® 70 Brentuximab Vedotin SGN 70 Receives Complete Response 70 Epothilone D 70 Lupus Drug 70 agonistic human 70 Vascular Disrupting Agent 70 BioSante Pharmaceuticals Announces 70 Anti Tumor Activity 70 Cutaneous T 70 Randomized Double Blind Placebo 70 markets XIFAXAN ® 70 NDA Submission 70 Telik logo TELINTRA 70 JAK Inhibitor 70 Submits Application 69 Announces FDA Clearance 69 Pivotal Trial 69 Patients Treated 69 selective A2A adenosine receptor 69 Inc. Nasdaq OXGN 69 peptidic compound 69 Announces Issuance 69 Receive Milestone Payment 69 2 inhibitor CYT# 69 sodium glucose cotransporter 69 Tyrosine Kinase Inhibitor 69 Cites Positive 69 Plus Ribavirin 69 % pramoxine HCl 69 Randomized Double blind 69 HDAC Inhibitor 69 Seliciclib CYC# 69 approved incretin mimetic 69 mGluR5 negative 69 FDA APPROVES 69 inflammatory PDE 69 FDA Okays 69 virus HCV protease inhibitor 69 Receives Patent 69 FDA Approvals 69 Investigational Drug 69 Double Blind Placebo 69 Controlled Trial 69 Transdermal Patch 69 Announces License Agreement 69 Develop Novel 69 Pivotal Trials 69 diarrhea fatigue asthenia 69 Therapeutic Competitors companiesandmarkets.com adEgemonye 69 Elagolix 69 Dose Finding 69 XL# anticancer compounds 69 Inhibits 69 MKC# 69 Announces Licensing Agreement 69 topical gel formulation 69 includes TOLAMBA TM 69 Patients Enrolled 69 Submits Supplemental 69 HCV Protease Inhibitor 69 Nasdaq VNDA 69 Janus kinase 69 orally administered inhibitor 69 Patent Covering 69 IND Filing 69 product platforms AZX# 69 Biogen Genentech 69 Shows Promising 69 dasatinib Sprycel ® 69 Achieves Milestone 69 Peginterferon 69 markets COLAZAL 69 evaluating picoplatin 69 novel synthetic PEGylated 69 Systemic Delivery 69 Controlled Study 69 Dose Ranging 69 anti botulism antibody 69 Factor Receptor 69 Receives Positive 69 Peginterferon Alfa 2a 69 Personalized Immunotherapy 69 Anti CD# Antibody 69 AN# topical anti 69 Amigal TM 69 Announce Merger Agreement 69 Luramist TM 69 Receives Conditional 68 Teva Provides Update 68 Combination Treatment 68 Topline Results 68 Nasdaq EPCT 68 Preclinical Study 68 Vascular Inflammation 68 Sign License Agreement 68 Anticancer Compound 68 Relapsed Refractory 68 Phase III Trials 68 selective phosphodiesterase 68 adecatumumab MT# 68 Relapsing Multiple Sclerosis 68 REG1 Anticoagulation System 68 Study Showed 68 6 sulfatase 68 Polymerase Inhibitor 68 Gets FDA Clearance 68 ABLYNX 68 Improves Outcomes 68 Closes Second Tranche 68 Bifunctional Muscarinic Antagonist Beta2 68 Pharmacokinetics PK 68 Antibody Drug Conjugate 68 Milestone Payment 68 Is Well Tolerated 68 R MSCRAMM 68 Exercises Option 68 Signs License Agreement 68 Dose Escalation 68 Announce Collaboration Agreement 68 Pharma Merck Serono 68 Signs Option Agreement 68 Significantly Improves 68 Crofelemer budesonide foam 68 AZX# Phase 68 Monotherapy 68 Novel Antibiotic 68 Significantly Reduces 68 Metastatic Colorectal Cancer 68 Investigational Agent 68 estrogen receptor beta agonist 68 2 methoxyestradiol 68 Nasdaq MNKD focuses 68 Prodrug 68 Million Milestone Payment 68 Sangamo BioSciences Announces 68 Newly Diagnosed Multiple Myeloma 68 novel VDA molecule 68 CYT# potent vascular disrupting 68 orally inhaled migraine 68 Small Molecule 68 Romidepsin 68 Drug Shows Promise 68 CD# CEA 68 Investigational Treatment 68 Shows Statistically Significant 68 developing adecatumumab 68 CHANGES IN THE COMPANY 68 please visit http:/www.vandapharma.com 68 Dose Escalation Study 68 Announces Commencement 68 CHEAP ONLINE PHARMACY LOW 68 Human Monoclonal Antibody 68 Successful Completion 68 albiglutide 68 Treatment Experienced 68 Vicriviroc 68 Gout Drug 68 ARRY # 68 RNAi Therapeutic 68 Testosterone MDTS R 68 Lenocta TM 68 Lung Cancer Drug 68 Disease Modifying 68 KSP inhibitor 68 Mg Usa 68 Secures Additional 68 Bosutinib 68 TRACON Pharmaceuticals 68 Patient Enrolment 67 EARNINGS LOOK AHEAD 67 By JENNIFER LEARN 67 Long Term Efficacy 67 Updates Status 67 Oral Cladribine 67 Diabetic Neuropathy 67 Grants Orphan Drug 67 Successfully Completes 67 SPRYCEL ® 67 lead Aganocide compound 67 Clinical Study Shows 67 TELINTRA R 67 balsalazide disodium Capsules 67 lintuzumab SGN 67 Inc. OTCBB ECTE 67 Diabetic Nephropathy 67 HCV RNA polymerase 67 Regains Compliance 67 Nasdaq HALO 67 lead molecular radiotherapeutic 67 Files Shelf Registration Statement 67 interferon gamma 1b 67 Collaborators Publish 67 Clinical Study 67 Awarded Qualifying Therapeutic 67 Study Demonstrates 67 Perifosine KRX 67 Therapeutic Antibody 67 Board Authorizes 67 Immunomedics Announces 67 Treatment Naive Patients 67 Multicenter Phase 67 systemic juvenile idiopathic 67 Vitrasert R 67 product candidate Lpathomab 67 Inc. www.micromet inc.com 67 telomerase therapeutic 67 PROCTOCORT R 67 Combination Therapy 67 antibody MAb 67 Novel Mechanism 67 Invites Investors 67 Pivotal Phase II 67 Maribavir 67 Anticancer Activity 67 Obtains Approval 67 pharmacogenomic translational research 67 topical antifungal product 67 THERAPEUTICS 67 humanized interleukin 6 67 Announces Successful 67 Aflibercept 67 Corp. NASDAQ CYTR 67 Expand Collaboration 67 negative allosteric modulator 67 Files Patent Application 67 Expands Scientific Advisory 67 Pharmaceuticals Initiates 67 Pafuramidine 67 Parathyroid Hormone 67 Mouse Model 67 PROVENGE ® 67 LymphoStat B belimumab 67 Pharmacyclics Announces 67 sapropterin dihydrochloride 67 Chronic Hepatitis B 67 Acquires Exclusive 67 Announces Termination 67 Desvenlafaxine Succinate 67 Prostate Cancer Vaccine 67 Obtains FDA 67 Previously Untreated 67 IN PATIENTS WITH 67 Receives SFDA Approval 67 Ovitrelle R Serostim 67 NDTV HINDU # 67 particularly SANCTURA XR 67 neuropathic pain metabolic diseases 67 Inc Therapeutic Competitors 67 Migraine Drug 67 Receives Favorable 67 Efficacy Results 67 Announces Completion 67 sarcoma melanoma 67 OTCBB FCSC 67 Phase Ib clinical trials 67 SAR# [002] 67 Exherin 67 4SC AG ISIN DE# 67 MBRX 67 Novartis Novo Nordisk 67 novel emulsion formulation 67 Receptor Antagonists 67 methylnaltrexone bromide 67 Preclinical Models 67 TM Aganocide 67 Ecallantide 67 PNP inhibitor 67 developing ACAPODENE 67 Glufosfamide 67 Ceflatonin R 67 R memantine HCl 67 Generic Version 67 mGluR2 positive 66 investigational humanized monoclonal antibody 66 benzoic acid hyoscyamine sulfate 66 phenyl salicylate methylene blue 66 Awarded Patent 66 Announce Collaboration 66 VentiRx Pharmaceuticals 66 Safinamide 66 investigational oral inhibitor 66 refractory chronic lymphocytic 66 Launches Generic Version 66 mg OSMOPREP ® 66 COLAZAL ® 66 evaluating bafetinib 66 Boehringer Ingelheim MedImmune 66 signal detection CTSD 66 Hypertensive Patients 66 rusalatide acetate 66 PEGylated anti 66 Regains NASDAQ 66 Flamel Technologies Announces 66 SHAREHOLDERS ARE STRONGLY ADVISED 66 PDGFR B 66 Arthritis Drug 66 Patients Suffering 66 Submits Investigational 66 Shows Promise Against 66 Provides Update Regarding 66 Pruvel TM 66 Phase IIa Trial 66 Develops Novel 66 R lenalidomide 66 vapreotide acetate 66 Nuvelo Announces 66 Jumps Higher 66 Ispinesib SB # 66 Successfully Completed 66 molecular imaging radiopharmaceutical 66 Regains Compliance With 66 NOTE POSIDUR ™ 66 Metformin HCl 66 Phase 2a Study 66 MEK Inhibitor 66 Acetate Rectal Suppositories 66 Initiate Phase II 66 Rheumatoid Arthritis Drug 66 familial amyloidotic polyneuropathy FAP 66 Osteoporosis Drug 66 Biopharmaceuticals AG 66 Recommends Approval 66 Soft Tissue Sarcoma 66 Mg Uk 66 Omacetaxine 66 Shows Efficacy 66 Amends Agreement 66 Inc. ProMetic www.prometic.com 66 receptor tyrosine kinase inhibitor 66 Milestone Payments 66 Acute Attacks 66 Novel Anti Inflammatory 66 RNAi Therapeutics 66 receiving INTRON 66 Placebo Controlled 66 interferon beta 1a infertility 66 Sagent Pharmaceuticals Announces 66 Announce Completion 66 Placebo Controlled Trial 66 Attenuates 66 Announces Cancellation 66 acetonide FA 66 Nicotine Vaccine 66 novel histone deacetylase 66 Genentech Wyeth Pharmaceuticals 66 Oral Formulation 66 Receives Conditional Approval 66 Novel Inhibitor 66 Cyclooxygenase Inhibiting Nitric Oxide 66 Receives Tentative Approval 66 Phase Ib Clinical Trial 66 Induces 66 hypoxia activated prodrug 66 Angiotensin Converting Enzyme 66 Hematological Malignancies 66 derivatives Radilex TM 66 including eniluracil ADH 66 trastuzumab Herceptin R 66 Atripla combines 66 Ofatumumab 66 Medoxomil 66 Mutually Agree 66 First Patient Treated 66 essential thrombocythemia ET 66 Rigel R# 66 Statistically Significant 66 INSPIRE Trial Phase III 66 Secures Financing 66 Multicenter Randomized 66 FOLFOX6 chemotherapy regimen 66 CYP#A# CYP#D# 66 Infected Patients 66 sanofi aventis Bayer Schering 66 Nasdaq CTIC 66 Nucleoside 66 Plaque Psoriasis 66 PRICE GREAT DISCOUNT FREE 66 Histone Deacetylase 66 Antiviral Activity 66 carcinoma mCRC 66 Antigen Specific 66 TRIOLEX ™ 66 OTCBB DORB 66 Low Dose 66 induced macular edema 66 Novel Compound 66 Announces Filing 66 Melphalan 66 Pulmonary Arterial Hypertension 66 Tesetaxel 66 Announce Licensing Agreement 66 TNF Tumor Necrosis Factor 66 Transdermal System 66 ABL inhibitor 66 Begins Shipment 66 ATRA IV 66 Completes Initial 66 Cloretazine ® 66 Postmenopausal Osteoporosis 66 Early Relapsing Multiple 66 Announces Immediate Availability 66 Suppository Hydrocortisone Acetate Rectal 66 Alvine Pharmaceuticals 66 Carboplatin Paclitaxel 66 Commercialize 66 VIVUS Announces 66 TRANSDUR ® 66 PHASE III 66 Announces Effective Date 66 Phase III Clinical Trials 66 Albuferon TM 66 investigational pan BCR 66 diarrhea predominant irritable 66 Xeloda ® 66 NicVAX TM 66 Pralatrexate 66 BIOTECHNOLOGY SOURCE 65 MKC# MKC# PP 65 sapropterin dihydrochloride Phase 65 Staphylococcus aureus Immune Globulin 65 Merck OSI Pharmaceuticals 65 Patent Issued 65 cetuximab Erbitux R 65 Announces Signing 65 dihydrochloride Tablets 65 Am J Obstet 65 GATTEX TM 65 Synta Announces 65 allosteric modulator NAM 65 Identifies Potential 65 Corp. AMEX CVM 65 DNA methyltransferase inhibitors 65 Expanded Indication 65 generation Hsp# inhibitor 65 FACTORS THAT MIGHT CAUSE 65 Receives Approval 65 Vaccine Candidate 65 Bradmer Pharmaceuticals 65 RANK Ligand inhibitor 65 NEWS TONIGHT NDTV 65 Announce Receipt 65 Orthop Surg 65 include Phenoptin TM 65 Prospective Randomized 65 combines bupropion 65 Receives Notice 65 Diabetic Neuropathic Pain 65 highly selective inhibitor 65 lexidronam injection 65 IIa Clinical Trial 65 Versus Placebo 65 subsidiaries visit http:/www.apricusbio.com 65 Oral Insulin Capsule 65 agonist compounds 65 developing Zerenex ferric 65 Demonstrates Sustained 65 evaluating mipomersen 65 toenail onychomycosis 65 Announces Receipt 65 Advanced Prostate Cancer 65 Epratuzumab 65 MT# MEDI 65 Sinks Lower 65 novel orally inhaled 65 R Saizen R 65 ADP receptor antagonist 65 candidates Azedra TM 65 FEMALES SHOULD BE ADVISED 65 Milestone Payment From 65 Luveris R Ovidrel R 65 から 65 Q3 Loss Widens 65 polymerase inhibitor 65 Proven Effective 65 Orally administered 65 Pegloticase 65 Forodesine 65 Potent Antiviral Activity 65 Demonstrates Statistically Significant 65 STERIS Corporation Announces 65 NASDAQ ENMD 65 platform HDL Mimetic 65 Fungal Infections 65 Provides Update 65 UNCERTAINTY OF FUTURE FINANCIAL 65 Granulocyte Colony Stimulating Factor 65 Novacort R 65 Efficacy Trial 65 DOR BioPharma Announces 65 Receives Clearance 65 Confirms Significant 65 CysDisplay R 65 JZP 65 Phase #b/#a clinical 65 Metabolic Efficiency 65 markets HP Acthar 65 Q2 Loss Narrows 65 Ondansetron Orally Disintegrating Tablets 65 OPXA 65 CD4 monoclonal antibody 65 Nicotine Conjugate Vaccine 65 ALN HPN 65 Receives Regulatory 65 Intravenous Formulation 65 liposomal formulation 65 oral proteasome inhibitor 65 sodium thiosulfate STS 65 NASDAQ MNKD focuses 65 Peginterferon alfa 2b 65 Zorbtive TM 65 Testosterone Gel 65 Obtains Exclusive License 65 Vidaza R 65 CCX# B 65 novel MetAP 2 65 Completes Successful 65 Namenda Memantine HCl 65 pan HDAC inhibitor 65 Patients Receiving 65 products MKC# PP 65 clinical trials Archexin ® 65 novel antimitotic agent 65 COMIC REEL WRAP 65 IG HCR ;) CO 65 targeted radiotherapeutic 65 Frozen Shoulder syndrome Adhesive 65 Advanced Renal Cell 65 Avise MCV SM 65 Diffuse Large B 65 compound PMX # 65 Randomized Phase III 65 monoclonal antibody IgG1 Mab 65 Cerebril TM 65 Voluntarily Withdraw 65 developing ostarine selective 65 Inhalation Aerosol 65 ENL recurrence 65 Ondansetron Injection USP 65 Sodium Sulfate Sodium Chloride 65 Relapsed Multiple Myeloma 65 Oral Suspension Oral Suspension 65 Phospholipase A2 65 Capsules CII 65 % hydrocortisone acetate 65 HGS ETR2 65 Obtains License 65 Aztreonam Lysine 65 Inhalation Solution 65 Civacir TM Hepatitis C 65 COMUNICADO DE 65 NASDAQ MIPI 65 Nasdaq MNKD focused 65 Regains Full 65 Signs Licensing Agreement 65 Completes Financing 65 Effectively Treats 65 Announces Shareholder Approval 65 candidates Azedra 65 HUMAN GENOME SCIENCES 65 Announces Favorable 65 LymphoStat B TM 65 Ozarelix 65 proprietary intranasal insulin 65 OTC BB PVCT 65 Tumor Targeting 65 CHEAP ONLINE PHARMACY BEST 65 AnaSpec Introduces 65 Reduces Risk 65 oral Hsp# inhibitor 65 Merck Serono Nycomed 65 dextromethorphan quinidine 65 Settles Litigation 65 R bisoprolol Euthyrox 65 Q3 Loss Narrows 65 Therapeutic Vaccine 65 alfa 2a 65 Lung Cancer Trial 65 Closes Previously Announced 65 ketoconazole USP Gel 65 including cyclosporine methotrexate 65 Omigard TM omiganan pentahydrochloride 65 oral dihydropyrimidine dehydrogenase DPD 65 Renal Cell Carcinoma 65 submitted supplemental Biologics 65 bevacizumab Avastin R 65 Epilepsy Drug 65 ALN PCS 65 Receives Notification 65 selectin antagonist 65 evaluating tivozanib 65 OTCBB GETA 65 MCSP respectively 65 TNF Blockers 65 Significantly Increases 65 Genentech GlaxoSmithKline 65 Closes Financing 65 candidate XP# 65 Palifosfamide 65 selective antagonist 65 candidate AQ4N 65 Discontinues 65 Hepatitis C Genotype 65 II TRISENOX R 65 oral ghrelin agonist 65 Subgroup Analysis 65 Subsidiary Enters 65 IMPDH inhibitor 65 Primary Hypercholesterolemia 65 oncolytic virus therapies 65 Matrix Phase 2b 65 Contrave# 65 Treat Anemia 65 Hemodialysis Patients 65 Treatment Resistant 65 Benign Prostatic Hyperplasia 65 highly selective adenosine 65 Demonstrate Significant 65 Plicera TM 65 Inks MOU 65 Taglich Brothers Initiates Coverage 65 Drug Eluting Stent System 65 Significantly Improved 65 Custirsen 65 Eluting Stent 65 imatinib Gleevec ® 65 Jointly Announce 64 Announce Commencement 64 Attains 64 generation purine nucleoside 64 Drug Resistant 64 Survival Benefit 64 Serdaxin ® 64 treatment naive genotype 64 R famotidine 64 Aurora Kinase 64 Naive Patients 64 cancer neuroendocrine tumor 64 Introduces Novel 64 Clinical Efficacy 64 Elderly Patients 64 Colaris Colaris AP 64 5 FU leucovorin 64 Emtriva Viread 64 Psoriasis Drug 64 TRANSDUR ™ 64 Nasdaq PGNX 64 Potassium Chloride Sodium Ascorbate 64 ADVANCE REVIEW 64 Supplemental Biologics License Application 64 sunitinib Sutent ® 64 & PRODUCT DEFINITIONS 64 Chronic Myeloid Leukemia 64 please visit http:/www.supergen.com 64 Sirolimus Eluting Stent 64 NS5B polymerase 64 registrational Phase 64 ALTROPANE R 64 Veronate R 64 COLAZAL R 64 Resistant Hypertension 64 multicenter Phase III 64 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 64 phenylalanine ammonia lyase 64 Commences 64 XL# XL# 64 CybeRelease Decliners 64 alpha 2b 64 Postmenopausal Women 64 arsenic trioxide injection 64 Inc. NASDAQ SIRT 64 SABER ™ 64 Anti Inflammatory 64 histone deacetylase HDAC inhibitor 64 includes investigational compounds 64 Successfully Treated 64 severe oral mucositis 64 class anticancer quinolone 64 submitted Biologics License 64 Entereg R 64 Prodarsan R 64 Adjuvant Therapy 64 R metformin Concor 64 BiovaxID TM 64 Lispro 64 influenza BCX# purine nucleoside 64 lead heptagonist compound 64 GVAX ® 64 Schizophrenia Drug 64 STEALTH C 64 induced mucositis 64 ALN TTR 64 HGS ETR1 mapatumumab 64 vesicular monoamine transporter 64 Unanimously Recommends Approval 64 Recurrent Glioblastoma 64 Vitro Activity 64 soluble tumor necrosis 64 Joint Surg Am 64 Gets Bearish Confirmation 64 Demonstrates Efficacy 64 PEG IFN 64 clinical trials Archexin 64 Voreloxin 64 transthyretin mediated amyloidosis ATTR 64 5 fluorouracil leucovorin 64 Peginterferon alfa 2a 64 Cell Transplants 64 Announces Granting 64 By JAMAAL ABDUL 64 Q4 Loss Widens 64 nilotinib Tasigna ® 64 Cyclophosphamide 64 Aloxi ® 64 administered concomitantly 64 beta 1a 64 PHARM 64 Hydrochlorothiazide Tablets 64 Inc. Nasdaq IMGN 64 Cholesterol Lowering Drug 64 Combination Clinical Trial 64 chronic eosinophilic leukemia 64 ODT metoclopramide HCl PEPCID 64 Relapsed 64 novel topoisomerase 64 Trastuzumab DM1 64 Genotyping Test 64 Cetrorelix 64 Immunotherapeutic 64 erlotinib Tarceva R 64 Slow Progression 64 Archexin 64 Updates Shareholders 64 PATENT FOR 64 Annamycin 64 Extends Collaboration 64 Provides Guidance 64 Child Adolesc Psychiatry 64 highly purified pasteurized 64 compound INCB# 64 Proc Am Soc 64 Preclinical Efficacy 64 Irinotecan 64 oral Janus kinase 64 Node Positive 64 LUX Lung 64 NYSE Amex YMI 64 Blood Pressure Drug 64 Replacement Therapy 64 Subtypes 64 Inc. NASDAQ VSGN 64 brand ciclesonide HFA 64 Enter Into 64 Modulates 64 5 HT3 antagonist 64 cake Mah Karn 64 5 HT6 64 Molecular Diagnostic Test 64 Generic Versions 64 J Allergy Clin 64 Advanced Colorectal Cancer 64 Dendritic Cells 64 OVER FINANCIAL REPORTING 64 NU# direct 64 Bortezomib 64 Myelofibrosis 64 initiated Phase 1b 64 KRYSTEXXA TM pegloticase 64 GILEAD SCIENCES 64 Luveniq 64 myelodysplastic myeloproliferative diseases 64 Positive Opinion 64 please visit http:/www.atherogenics.com 64 Oral Laquinimod 64 Lanthanum Carbonate 64 Enters Agreement 64 Nasdaq PARD 64 BayStreet.ca Research Alert 64 Announces Dismissal 64 Augment TM 64 Inc. Nasdaq MITI 64 Bullish Average Crossover 64 Myeloma Patients 64 PPD Declares 64 Takeda Kyowa Hakko Kirin 64 Tumor Necrosis Factor 64 Vidaza ® 64 Integrase Inhibitor 64 Patents Covering 64 Initiates 64 Signs Agreements 64 Abiraterone Acetate 64 Romiplostim 64 Malignant Melanoma 64 Intravitreal 64 Completes Previously Announced 64 nausea dehydration dyspnea 64 Q2 Loss Widens 64 norepinephrine reuptake inhibitor 64 IV FENTORA R 64 WRX STi +# mins 64 Bullish Technical Alert 64 Novel Therapeutic 64 Shareholders Approve Merger 64 Suppl 64 PRICES GREAT DISCOUNTS 64 Therapeutic Competitors Report 64 visit www.stemcellthera.com 64 VIVITROL ® 64 erlotinib Tarceva ® 64 docetaxel Taxotere R 64 #-#.#.# [001] 64 Panzem R NCD 64 humanized therapeutic 64 NEWS RELEASE THE COMPANY 64 RON Notch 64 Receives Marketing Authorization 64 Insulin Glargine 64 Coadministration 64 Novartis Organon 64 Interferon Beta 64 5 lipoxygenase activating 64 Bone Metastases 64 OTCBB OHRP 64 CTAP# Injection 64 SHARES SLIDING LOWER DOWN

Back to home page